NASDAQ · Biotechnology

ESLA (ESLA) Stock

$0.69 +8.00% NASDAQ: ESLA Healthcare

Valuation

MetricValue
Price$0.69
Market Cap$29.54M
P/E Ratio-2.80
P/B Ratio-3.99
P/S Ratio0.00
EPS (TTM)$-0.32
52-Week High$3.15
52-Week Low$0.63
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE121.72%
ROA-548.74%
ROCE131.75%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.14

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-11.0M$-7.0M$-9.0M$-13.0M
Net Profit$-2.0M$-11.0M$-7.0M$-9.0M$-13.0M
EPS$-0.05$-0.32$-0.21$-0.24$-0.35
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.0M$10.0M$4.0M$3.0M$3.0M
Total Liabilities$6.0M$3.0M$0$3.0M$14.0M
Cash$4.0M$0$4.0M$1.0M$1.0M
Borrowings$0$0$0$0$0

Latest News

ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma? Zacks Small Cap Research · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-16.0M$-3.0M$-2.0M
Investing Cash Flow$0$36.0M$5.0M$0$0
Financing Cash Flow$1.0M$-36.0M$4.0M$0$0
Net Cash Flow$4.0M$0$2.0M$1.0M$0
Free Cash Flow$-1.0M$-1.0M$-16.0M$-3.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.15
EV / EBITDA-2.99
FCF Yield-31.87%
Quick Ratio0.20
Interest Coverage0.00
Return 1Y-8.94%
Return 3Y-92.99%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
ATOS $2.53 -0.79% -0.58 $25.24M 0.00%
EXOZ $6.80 +0.15% -5.67 $63.11M 0.00%
GLSI $15.49 -0.90% -10.15 $227.37M 0.00%
IMMX $13.83 +0.04% -15.72 $752.38M 0.00%

About ESLA

ESLA is led by CEO Cheng Liu, publicly traded since 2021.

ESLA stock trades at $0.69 with a market capitalization of $29.54M. The stock is valued at a price-to-earnings (P/E) ratio of -2.80, price-to-book of -3.99, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.63 and $3.15, and currently trades 78.1% below its 52-week high.

On profitability, ESLA generates a return on equity (ROE) of 121.72% — well above the market average, a sign of a high-quality business, return on capital employed of 131.75%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1145.22 -1.24% JNJ Drug Manufacturers - General $275.95 -0.89% ABBV Drug Manufacturers - General $256.94 -1.26% MRK Drug Manufacturers - General $151.11 -0.81% UNH Medical - Healthcare Plans $397.94 -0.75% NVS Drug Manufacturers - General $160.25 -1.74% AZN Drug Manufacturers - General $163.51 -0.76% AMGN Drug Manufacturers - General $438.14 -1.35% TMO Medical - Diagnostics & Research $609.68 -1.41% NVO Biotechnology $47.51 +1.58% ABT Medical - Devices $109.04 +0.23% GILD Drug Manufacturers - General $150.34 -0.59%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides